NO20080168L - Aminoquinolin- og aminoquinoazolinkinasemodulatorer - Google Patents

Aminoquinolin- og aminoquinoazolinkinasemodulatorer

Info

Publication number
NO20080168L
NO20080168L NO20080168A NO20080168A NO20080168L NO 20080168 L NO20080168 L NO 20080168L NO 20080168 A NO20080168 A NO 20080168A NO 20080168 A NO20080168 A NO 20080168A NO 20080168 L NO20080168 L NO 20080168L
Authority
NO
Norway
Prior art keywords
compounds
aminoquinoline
trkb
flt3
aminoquinoazoline
Prior art date
Application number
NO20080168A
Other languages
English (en)
Inventor
Alexander J Kim
Nand Baindur
Michael David Gaul
Kevin Douglas Kreutter
Guozhang Xu
Christian Andrew Baumann
Bao-Ping Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080168(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20080168L publication Critical patent/NO20080168L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår aminokinolin og aminokinazolin forbindelser med Formel I: hvori R1, R2, R3, B, Z, Q, p, q og X er som definert heri, anvendelsen av slike forbindelser som protein tyrosin kinase modulatorer, særlig inhibitorer av FLT3 og/eller TrkB, anvendelsen av slike forbindelser for å redusere eller inhibere kinase aktivitet til FLT3 og/eller TrkB i en celle eller hos et subjekt, og anvendelsen av slike forbindelser for å hindre eller behandle en celle proliferativ forstyrrelse og/eller forstyrrelser relatert til FLT3 og/eller TrkB hos et subjekt. Foreliggende oppfinnelse angår ytterligere farmasøytiske sammensetninger som innbefatter forbindelsene i følge oppfinnelsen og fremgangsmåter for behandling av tilstander slike som kreft og andre celle proliferative forstyrrelser.
NO20080168A 2005-06-10 2008-01-09 Aminoquinolin- og aminoquinoazolinkinasemodulatorer NO20080168L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68938205P 2005-06-10 2005-06-10
US74732106P 2006-05-16 2006-05-16
PCT/US2006/022195 WO2006135649A2 (en) 2005-06-10 2006-06-07 Aminoquinoline and aminoquinazoline kinase modulators

Publications (1)

Publication Number Publication Date
NO20080168L true NO20080168L (no) 2008-03-07

Family

ID=37101582

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080168A NO20080168L (no) 2005-06-10 2008-01-09 Aminoquinolin- og aminoquinoazolinkinasemodulatorer

Country Status (17)

Country Link
US (1) US20070004763A1 (no)
EP (1) EP1899319A2 (no)
JP (1) JP2008543762A (no)
KR (1) KR20080028913A (no)
AR (1) AR057062A1 (no)
AU (1) AU2006258059A1 (no)
BR (1) BRPI0611621A2 (no)
CA (1) CA2611378A1 (no)
CR (1) CR9647A (no)
EA (1) EA200800014A1 (no)
EC (1) ECSP077998A (no)
GT (1) GT200600254A (no)
IL (1) IL187685A0 (no)
NO (1) NO20080168L (no)
PE (1) PE20070113A1 (no)
TW (1) TW200716598A (no)
WO (1) WO2006135649A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066642A1 (en) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
JP6903585B2 (ja) * 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
EP3394061B1 (en) 2015-12-23 2020-03-11 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
CN109311816A (zh) * 2016-05-04 2019-02-05 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
EP3496715B1 (en) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
US10414774B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
CN111372587B (zh) 2017-09-08 2024-01-09 里兰斯坦福初级大学理事会 Enpp1抑制剂以及它们用于治疗癌症的用途
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. INHIBITORS OF CYCLINE-DEPENDENT KINASES
WO2020006497A1 (en) 2018-06-29 2020-01-02 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
JPWO2020017569A1 (ja) * 2018-07-17 2021-12-02 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
US20220226299A1 (en) * 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
CA3147422A1 (en) * 2019-07-17 2021-01-21 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
JP2023535096A (ja) * 2020-07-23 2023-08-15 シトシンラボ セラピューティクス カンパニー， リミテッド キナーゼ阻害活性を有する化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT344178B (de) * 1974-07-25 1978-07-10 Pfizer Verfahren zur herstellung von neuen chinazolinverbindungen und deren saeureadditionssalzen und optisch aktiven formen
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
EP1382603B1 (en) * 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
MXPA05000081A (es) * 2002-06-27 2005-04-11 Schering Ag Quinolinas sustituidas antagonistas del receptor ccr5.
DK1678166T3 (da) * 2003-10-14 2009-11-09 Univ Arizona State Proteinkinaseinhibitorer

Also Published As

Publication number Publication date
IL187685A0 (en) 2008-08-07
TW200716598A (en) 2007-05-01
CR9647A (es) 2008-09-09
AR057062A1 (es) 2007-11-14
WO2006135649A3 (en) 2007-02-15
GT200600254A (es) 2007-01-12
JP2008543762A (ja) 2008-12-04
AU2006258059A1 (en) 2006-12-21
EA200800014A1 (ru) 2008-06-30
WO2006135649A2 (en) 2006-12-21
KR20080028913A (ko) 2008-04-02
PE20070113A1 (es) 2007-02-09
US20070004763A1 (en) 2007-01-04
BRPI0611621A2 (pt) 2010-09-21
EP1899319A2 (en) 2008-03-19
CA2611378A1 (en) 2006-12-21
ECSP077998A (es) 2008-01-23

Similar Documents

Publication Publication Date Title
NO20080168L (no) Aminoquinolin- og aminoquinoazolinkinasemodulatorer
NO20083013L (no) Triazolopyridaziner som tyrosinkinasemodulatorer
NO20080163L (no) Aminopyrimidiner som kinasemodulatorer
NO20080174L (no) Alkylquinolin- og alkylquinazolinkinasemodulatorer
NO20080161L (no) Aminopyrimidiner som kinasemodulatorer
NO20080162L (no) Tienopyrimidin og tienopyrimidinderivater som FLT-3 kinaseinhibitorer
NO20061194L (no) Mitotiske kinesininbibitorer
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20070506L (no) Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer.
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
WO2008035209A3 (en) Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
ATE554087T1 (de) Neue kinaseinhibitoren
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
NO20090608L (no) Tyrosinkinaseinhibitorer
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
NO20080417L (no) Benzosykloheptapyridiner som inhibitorer av reseptortyrosinkinasen MET
EA200870454A1 (ru) Способ ингибирования c-kit киназы
ATE527264T1 (de) Kondensierte heterozyklische verbindungen als hemmer von proteinkinasen
UA109764C2 (uk) Похідні ізохінолінону, композиція на їх основі та застосування як інгібіторів рі3k
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren
UY29587A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application